RecruitingRecruiting
Experiences w/ & Attitudes Towards Immune Chckpt Inhibitors in NSCLC Patients Single Center Survey Based Study
NCT07339254 · University of Southern California
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Experiences With and Attitudes Towards Immune Checkpoint Inhibitors in Patients With Non-Small Cell Lung Cancer (NSCLC) - A Single Center, Survey-Based Study
About this study
PRIMARY OBJECTIVES:
I. To assess patient satisfaction with receiving IV immune checkpoint inhibitors, reflecting whether the patient thought that the experience was safe, convenient, comfortable and proceeded smoothly.
II. To assess patient preference for IV versus home SC ICI administration.
OUTLINE: This is an observational study.
Patients complete surveys on study.
Eligibility criteria
Inclusion Criteria:
* \* Age ≥ 18 years.
* \* Patients must have histopathologically/cytologically confirmed non-small cell lung cancer, currently receiving Atezolizumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab (i.e. the patient has already received at least one cycle of therapy)
* \* Previous chemotherapy/radiotherapy/targeted/immunotherapy is allowed at any prior timepoint.
* \* Ability to understand and the willingness to sign a written informed consent or presence of a surrogate decision maker who can give consent.
Exclusion Criteria:
* \* Patients is unable to consent for themselves
* \* Patient has not yet completed the 1st cycle of ICI-based therapy
Study design
Enrollment target: 40 participants
Age groups: adult, older_adult
Timeline
Starts: 2026-03-12
Estimated completion: 2028-03-12
Last updated: 2026-03-16
Interventions
Other: Non-Interventional Study
Primary outcomes
- • Strength of patient perception of Intravenous (IV) Immune Checkpoint Inhibitor (ICI) therapy (At Baseline through study completion, up to 1 year.)
- • Patient interest in home SC ICI administration vs. IV ICI administration at the infusion center (At Baseline through study completion, up to 1 year.)
Sponsor
University of Southern California · other
With: National Cancer Institute (NCI), Bristol-Myers Squibb
Contacts & investigators
InvestigatorRobert Hsu · principal_investigator, University of Southern California
All locations (2)
Los Angeles General Medical CenterRecruiting
Los Angeles, California, United States
USC / Norris Comprehensive Cancer CenterRecruiting
Los Angeles, California, United States